Linda C Knight

US Patent:

20100284921, Nov 11, 2010

Filed:

May 10, 2010

Appl. No.:

12/776503

Inventors:

JENNIFER GORDON - PHILADELPHIA PA, US
LINDA KNIGHT - BRYN MAWR PA, US

Assignee:

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - PHILADELPHIA PA

International Classification:

A61K 49/00
G01N 33/574
A61P 35/00

US Classification:

424 91, 435 723

Abstract:

This invention provides constructs comprising a targeting member immobilized on a detectable particulate, in which binding of the targeting member to a target structure on a surface of a cancer cell triggers internalization of the construct. Such constructs can be used to identify or monitor cancer cells in cell cultures or in a tissue. Such construct can also be used to kill or prevent growth of cancer cells in vivo. Also included in the invention are methods for killing or preventing growth of cancer cells in vivo.

US Patent:

48679631, Sep 19, 1989

Filed:

Jan 29, 1987

Appl. No.:

3/470086

Inventors:

Alan H. Maurer - Wynnewood PA
Linda C. Knight - East Windsor NJ
Jeffrey A. Siegel - Voorhees NJ

Assignee:

Temple University of the Commonwealth System of Higher Education - Philadelphia PA

International Classification:

A61K 4900

US Classification:

424 9

Abstract:

Nuclear magnetic resonance imaging of animal or human tissue is enhanced when a paramagnetic pyrophosphate compound is administered intraveneously as a contrast agent. The contrast agent is particularly useful in magnetic resonance imaging of area of tissue calcification, such as acute myocardial infarctions. Specific localization of paramagnetic pyrophosphate in ischemic and necrotic muscle cells at the periphery of a myocardial infarction makes accurate localization and sizing of the central infarct and peri-infarct zones possible.

US Patent:

52884902, Feb 22, 1994

Filed:

Nov 25, 1991

Appl. No.:

7/799699

Inventors:

Andrei Z. Budzynski - Glenside PA
Linda C. Knight - East Windsor NJ
Ahmed A. Hasan - Glenside PA

Assignee:

Temple University of the Commonwealth System of Higher Education - Philadelphia PA

International Classification:

A61K 37547
A61K 3718

US Classification:

424 9464

Abstract:

Thrombolytic hybrids are formed as covalent or non-covalent complexes of fibrin fragments and plasminogen activator molecules. Native plasmin degradation fragments of fibrin or non-native fibrin fragments are covalently or non-covalently linked to plasminogen activators such as t-PA, scu-PA, urokinase, streptokinase, and the like. Useful native fibrin fragments which may be utilized to form complexes with plasminogen activators include fragments E. sub. 1, E. sub. 2, E. sub. 3, D and DD, and (DD)E complex. The fibrin fragment component targets the hybrid to vascular thrombi, immobilizing the plasminogen activator molecule onto the fibrin surface of the thrombus. Once localized on a thrombus surface, the plasminogen activator component of the hybrid activates only the clot-surface bound plasminogen transported by the fibrin fragment vehicle, without significant systemic activation of plasminogen. The hybrids are strong potentiators of plasminogen activator activity, generating more plasmin from fibrin-surface bound plasminogen than the plasminogen activator molecule alone. The hybrids have a longer half-life in circulation than the corresponding unprotected plasminogen activator molecules.

US Patent:

53806468, Jan 10, 1995

Filed:

Oct 19, 1992

Appl. No.:

7/965674

Inventors:

Linda C. Knight - Moorestown NJ
Alan H. Maurer - Wynnewood PA

Assignee:

Temple University of the Commonwealth System of Higher Education - Philadelphia PA

International Classification:

A61K 4902
G01N 3353

US Classification:

424 169

Abstract:

Radiolabelled polypeptides derived from the Viperidae disintegrins are provided as well as a method for the detection of venous and arterial thrombi, pulmonary emboli and tumors or abscesses that have a thrombus component. Compositions suitable for parenteral administration comprising the radiolabelled polypeptides and a pharmaceutically acceptable carrier are also provided.